Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03030222 · ClinicalTrials.gov registry record · Phase 4
Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
A Phase 4 study, sponsored by Saint Luke's Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
NCT03030222: Completed Phase 4 study, sponsored by Saint Luke's Health System.
NCT03030222 is a Phase 4 study that has completed, run by Saint Luke's Health System. The registered enrollment target is 65 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03030222, a Phase 4 study, has completed, sponsored by Saint Luke's Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
Study Summary
The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a CardioMEMs device (a wireless hemodynamic monitoring system) implanted for non-study related clinical reasons.
Primary Outcome
Change in pulmonary artery diastolic pressure from baseline to end of treatment period (defined as average of pulmonary artery diastolic pressure measurements between weeks 8-12) between empagliflozin and placebo
Interventions
- DRUG Placebo Oral Tablet
- DRUG Empagliflozin 10 mg Tab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2020-03-10 |
| Phase | Phase 4 |
What the finished NCT03030222 record still lists
NCT03030222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03030222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03030222 about?
NCT03030222 is a clinical study titled "Empagliflozin Impact on Hemodynamics in Patients With Heart Failure". The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, on hemodynamic parameters (pulmonary artery diastolic pressure) in patients with heart failure (reduced or preserved ejection fraction, ischemic or non-ischemic etiology) who already have a Cardio...
What is the current status of trial NCT03030222?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2017-07-05. Estimated completion is 2020-03-10.
What interventions are being tested in trial NCT03030222?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Empagliflozin 10 mg Tab (DRUG).
Who is sponsoring clinical trial NCT03030222?
This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03030222's enrollment target sits among peer trials
65 1091st of 2000 higher than 903 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI